Education
About Us
Working with TipRanks
Follow Us
Ondine Biomedical, Inc. (GB:OBI)
LSE:OBI
OBI Stock Chart & Stats
8.75 p
-0.23 p(-2.61%)
At close: 4:00 PM EST
8.75 p
-0.23 p(-2.61%)
Day’s Range― - ―
52-Week Range7.50 p - 18.50 p
Previous CloseN/A
Volume7.12K
Average Volume (3M)160.07K
Market Cap
£53.13M
Enterprise Value74.31M
Total Cash (Recent Filing)£5.59M
Total Debt (Recent Filing)£557.09K
Price to Earnings (P/E)―
Beta0.50
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding518,366,940
10 Day Avg. Volume119,918
30 Day Avg. Volume160,072
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)6.29
Price to Sales (P/S)21.10
P/FCF Ratio-2.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)£12.20M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA 70.94% year-over-year revenue increase signals durable top-line momentum and expanding customer adoption. Sustained revenue growth provides more runway to invest in commercialization and R&D, supports operating leverage over time and enables scale to absorb fixed costs.
High Gross MarginA 64.47% gross margin indicates strong product-level economics, giving meaningful contribution per unit sold. This structural margin supports long-term profitability potential if operating expenses are controlled, and it helps the business cover SG&A and R&D as volumes increase.
Low LeverageA debt-to-equity ratio of ~0.024 reflects a conservative capital structure and limited fixed financial obligations. Low leverage preserves financial flexibility, reduces bankruptcy risk, and gives the company time to improve operations without large interest burdens or urgent refinancing needs.
Bears Say
Negative Operating Cash FlowNegative operating cash flow is a durable red flag: the business is not generating cash from core operations, forcing reliance on external financing or equity issuance. This constrains investment, risks dilution, and limits ability to scale or weather downturns without capital raises.
Lack Of ProfitabilityPersistently negative net and EBIT margins show the company has not yet converted revenue growth into profits. Continued losses reduce return on equity and shareholder value over time, and they increase dependency on funding until structural cost or revenue improvements occur.
Operational InefficienciesDespite healthy gross margins, the firm’s poor cash generation and noted operational inefficiencies indicate high operating costs or scaling challenges. These structural issues can prevent margin expansion, prolong unprofitability, and require management action to achieve sustainable economics.
Ondine Biomedical, Inc. News
OBI FAQ
What was Ondine Biomedical, Inc.’s price range in the past 12 months?
Ondine Biomedical, Inc. lowest share price was 7.50 p and its highest was 18.50 p in the past 12 months.
What is Ondine Biomedical, Inc.’s market cap?
Ondine Biomedical, Inc.’s market cap is £53.13M.
When is Ondine Biomedical, Inc.’s upcoming earnings report date?
Ondine Biomedical, Inc.’s upcoming earnings report date is May 14, 2026 which is in 65 days.
How were Ondine Biomedical, Inc.’s earnings last quarter?
Ondine Biomedical, Inc. released its earnings results on Sep 26, 2025. The company reported -0.016 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.016 p.
Is Ondine Biomedical, Inc. overvalued?
According to Wall Street analysts Ondine Biomedical, Inc.’s price is currently Overvalued.
Does Ondine Biomedical, Inc. pay dividends?
Ondine Biomedical, Inc. does not currently pay dividends.
What is Ondine Biomedical, Inc.’s EPS estimate?
Ondine Biomedical, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ondine Biomedical, Inc. have?
Ondine Biomedical, Inc. has 518,366,940 shares outstanding.
What happened to Ondine Biomedical, Inc.’s price movement after its last earnings report?
Ondine Biomedical, Inc. reported an EPS of -0.016 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ondine Biomedical, Inc.?
Currently, no hedge funds are holding shares in GB:OBI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ondine Biomedical, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.62%
12-Months-Change
Fundamentals
Return on Equity
-506.43%
Trailing 12-Months
Asset Growth
101.31%
Trailing 12-Months
Company Description
Ondine Biomedical, Inc.
Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
Technical Analysis
Avacta Group plc
―
SkinBioTherapeutics
―
4basebio UK Societas
―
Poolbeg Pharma Ltd.
―
Oxford Nanopore Technologies PLC
―
Options Prices
Currently, No data available
---